Testing for ‘Bad Cholesterol’ Doesn’t Tell the Whole Story

For years, doctors have focused on lowering “bad” LDL cholesterol to reduce heart attack risks. This approach has led to the widespread use of statins, which effectively lower LDL levels. However, LDL tests measure cholesterol within particles, not the number of particles themselves, which can vary between individuals with the same LDL level. This has led researchers to consider apolipoprotein B (apoB) as a better risk indicator since it counts all cholesterol-carrying particles. In 2026, major health organizations acknowledged apoB’s potential but still prioritize LDL in guidelines. Studies suggest apoB could prevent more heart attacks and strokes, yet it hasn’t become routine due to the longstanding success of LDL-focused treatments. QUESTION: How might the shift from LDL to apoB testing change the way we approach heart health in the future?